Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NOV
NOV logo

NOV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
19.460
Open
18.780
VWAP
19.01
Vol
4.10M
Mkt Cap
6.83B
Low
18.740
Amount
77.89M
EV/EBITDA(TTM)
7.21
Total Shares
360.40M
EV
7.27B
EV/OCF(TTM)
5.81
P/S(TTM)
0.80
NOV Inc. is an independent provider of equipment and technology to the upstream oil and gas industry. The Company's proprietary technology portfolio supports the industry’s drilling, completion, and production needs. It operates under two segments: Energy Products and Services, and Energy Equipment. The Company’s Energy Products and Services segment primarily designs, manufactures, rents, and sells products and equipment used in drilling, intervention, completion, and production activities. Its products include drill bits, downhole tools, premium drill pipe, drilling fluids, managed pressure drilling, integral and weld-on connectors for conductor strings and surface casing, completion tools, and artificial lift systems. Its Energy Equipment segment manufactures and supports the capital equipment and integrated systems needed for oil and gas exploration and production, both onshore and offshore, as well as for other marine-based, industrial and renewable energy markets.
Show More

Events Timeline

(ET)
2026-02-20
06:40:00
NOV Inc. Increases Quarterly Cash Dividend by 20% to 9 Cents per Share
select
2026-02-04 (ET)
2026-02-04
17:30:00
NOV Inc. Sees Q1 Revenue Down to $2.05B
select

News

Newsfilter
7.0
02-26Newsfilter
Novartis and Genentech Sue Over Drug Importation
  • Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
  • FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
  • Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
  • Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
CNBC
7.0
02-26CNBC
Novartis and Genentech Sue Over Illegal Drug Import Scheme
  • Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
  • Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
  • Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
  • Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
seekingalpha
8.0
02-20seekingalpha
NOV Declares 20% Increase in Quarterly Dividend to $0.09
  • Dividend Increase: NOV has declared a quarterly dividend increase from $0.075 to $0.09 per share, representing a 20% rise, which not only enhances investor return expectations but also reflects the company's financial stability in the current market environment.
  • Yield Metrics: The forward yield of this dividend stands at 1.78%, providing shareholders with a stable cash flow and enhancing the company's attractiveness in capital markets, particularly amid increasing economic uncertainties.
  • Earnings Report: In Q4 2025, NOV reported a GAAP EPS of $0.21, missing expectations by $0.04, while revenue of $2.28 billion exceeded forecasts by $110 million, demonstrating the company's resilience in revenue growth despite challenges.
  • Cost-Cutting Strategy: NOV plans to accelerate cost-cutting measures in 2026, targeting $100 million in annualized savings, a strategy aimed not only at addressing market challenges but also at supporting future profitability.
Newsfilter
8.0
02-20Newsfilter
NOV Inc. Increases Quarterly Cash Dividend by 20%
  • Dividend Increase: NOV Inc.'s Board of Directors has voted to raise its quarterly cash dividend by 20% to $0.09 per share, reflecting confidence in the company's financial health and likely attracting more investor interest.
  • Payment Schedule: The dividend will be payable on March 27, 2026, to stockholders of record as of March 13, 2026, ensuring that existing shareholders receive timely returns, thereby enhancing shareholder trust.
  • Company Background: With over 150 years of experience, NOV delivers technology-driven solutions in the global energy sector, helping customers produce energy safely and efficiently while minimizing environmental impact, highlighting its strategic importance in sustainability efforts.
  • Forward-Looking Statements: The company cautions that forward-looking statements may involve risks and uncertainties, urging investors to consider significant risk factors outlined in SEC filings to better assess future financial performance.
moomoo
8.0
02-20moomoo
NOV INC RAISES QUARTERLY DIVIDEND BY 20% TO $0.09 PER SHARE
  • Dividend Decrease: Novinc has reduced its quarterly dividend by 20%.
  • New Dividend Amount: The new dividend is set at $0.09 per share.
CNBC
9.5
02-13CNBC
European Pharma Companies Look Ahead to 2026
  • Patent Cliff Challenge: Pharmaceutical companies are facing an impending patent cliff, with billions in sales at risk, particularly Novartis, which anticipates a $4 billion loss in the first half of 2025, compelling firms to invest heavily in new drug pipelines to offset revenue losses.
  • Optimistic Pipeline Outlook: Companies like Novartis and AstraZeneca are emphasizing their robust drug pipelines, with Novartis projecting $59 billion in revenue for 2025 and AstraZeneca aiming for $80 billion by 2030, reflecting confidence in future growth despite current challenges.
  • M&A Strategic Focus: As companies seek to replenish revenue through acquisitions, there is a growing emphasis on the Chinese market as a significant source of innovation, with the frequency of deals with Chinese firms increasing markedly over the past decade.
  • Pricing Strategy Uncertainty: Although the immediate threat from Trump's Most Favored Nation drug pricing policy has diminished, pharmaceutical companies are still deliberating on how to balance pricing strategies between the U.S. and European markets to ensure market access and profitability for new drugs.
Wall Street analysts forecast NOV stock price to rise
11 Analyst Rating
Wall Street analysts forecast NOV stock price to rise
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
16.00
Averages
19.18
High
23.00
Current: 0.000
sliders
Low
16.00
Averages
19.18
High
23.00
Goldman Sachs
Ati Modak
Sell
maintain
$17 -> $20
AI Analysis
2026-03-04
Reason
Goldman Sachs
Ati Modak
Price Target
$17 -> $20
AI Analysis
2026-03-04
maintain
Sell
Reason
Goldman Sachs analyst Ati Modak raised the firm's price target on NOV Inc. to $20 from $17 and keeps a Sell rating on the shares. While geopolitical risks could create near-term challenges, there are early signs of dislocations which could present opportunities when compared to fundamentals, the analyst tells investors in a research note. The firm does not expect current geopolitical concerns to meaningfully impact long-term customer plans as significant portions of the activity increases are structural in offsetting decline rates and increasing production capacity, the firm says.
Citi
Neutral
maintain
$17 -> $20
2026-02-11
Reason
Citi
Price Target
$17 -> $20
2026-02-11
maintain
Neutral
Reason
Citi raised the firm's price target on NOV Inc. to $20 from $17 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NOV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Nov Inc (NOV.N) is 15.67, compared to its 5-year average forward P/E of 6.66. For a more detailed relative valuation and DCF analysis to assess Nov Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
6.66
Current PE
15.67
Overvalued PE
65.52
Undervalued PE
-52.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.14
Current EV/EBITDA
7.48
Overvalued EV/EBITDA
14.80
Undervalued EV/EBITDA
5.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.83
Current PS
0.70
Overvalued PS
0.99
Undervalued PS
0.66

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Give me mid and small-cap companies
Intellectia · 130 candidates
Sector: Energy, Energy - Fossil Fuels, Renewable EnergyRegion: USMarket Cap Category: mid, smallList Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
RRC logo
RRC
Range Resources Corp
9.85B
NXE logo
NXE
Nexgen Energy Ltd
8.20B
HESM logo
HESM
Hess Midstream LP
8.07B
FRO logo
FRO
Frontline Plc
7.77B
MUSA logo
MUSA
Murphy USA Inc
7.75B
KNTK logo
KNTK
Kinetik Holdings Inc
7.42B
stocks with increasing insiders buyers
Intellectia · 16 candidates
Market Cap: >= 3.00BDividend Yield Ttm: >= 1.50Insider Transactions: NetPurchaseWeekly Average Turnover: >= 1,000,000Pe Ttm: 10 - 20
Ticker
Name
Market Cap$
top bottom
CI logo
CI
Cigna Group
73.44B
ET logo
ET
Energy Transfer LP
60.60B
F logo
F
Ford Motor Co
54.87B
CINF logo
CINF
Cincinnati Financial Corp
25.24B
BAH logo
BAH
Booz Allen Hamilton Holding Corp
11.59B
WAL logo
WAL
Western Alliance Bancorp
9.99B
low stock prices
Intellectia · 80 candidates
Market Cap: 300.00M - 10.00BPrice: <= $20.00Relative Vol: >= 1.50Beta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
KT logo
KT
KT Corp
9.47B
GGB logo
GGB
Gerdau SA
8.43B
NOV logo
NOV
Nov Inc
6.71B
FNB logo
FNB
FNB Corp
6.36B
CIG logo
CIG
Energy of Minas Gerais Co
5.98B
SRAD logo
SRAD
Sportradar Group AG
5.40B

Whales Holding NOV

A
azValor Asset Management SGIIC, S.A.U.
Holding
NOV
+34.33%
3M Return
H
Heartland Advisors, Inc.
Holding
NOV
+7.50%
3M Return
H
Hotchkis and Wiley Capital Management, LLC
Holding
NOV
+0.60%
3M Return
G
Greenhaven Associates Inc
Holding
NOV
-3.62%
3M Return
F
First Pacific Advisors, LP
Holding
NOV
-3.89%
3M Return
P
Pzena Investment Management, Inc.
Holding
NOV
-7.48%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Nov Inc (NOV) stock price today?

The current price of NOV is 18.84 USD — it has decreased -0.63

What is Nov Inc (NOV)'s business?

NOV Inc. is an independent provider of equipment and technology to the upstream oil and gas industry. The Company's proprietary technology portfolio supports the industry’s drilling, completion, and production needs. It operates under two segments: Energy Products and Services, and Energy Equipment. The Company’s Energy Products and Services segment primarily designs, manufactures, rents, and sells products and equipment used in drilling, intervention, completion, and production activities. Its products include drill bits, downhole tools, premium drill pipe, drilling fluids, managed pressure drilling, integral and weld-on connectors for conductor strings and surface casing, completion tools, and artificial lift systems. Its Energy Equipment segment manufactures and supports the capital equipment and integrated systems needed for oil and gas exploration and production, both onshore and offshore, as well as for other marine-based, industrial and renewable energy markets.

What is the price predicton of NOV Stock?

Wall Street analysts forecast NOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOV is19.18 USD with a low forecast of 16.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nov Inc (NOV)'s revenue for the last quarter?

Nov Inc revenue for the last quarter amounts to 2.28B USD, decreased -1.34

What is Nov Inc (NOV)'s earnings per share (EPS) for the last quarter?

Nov Inc. EPS for the last quarter amounts to -0.21 USD, decreased -151.22

How many employees does Nov Inc (NOV). have?

Nov Inc (NOV) has 31605 emplpoyees as of March 11 2026.

What is Nov Inc (NOV) market cap?

Today NOV has the market capitalization of 6.83B USD.